Droperidol: Why It's A Hospital-Only Drug

Droperidol is an antidopaminergic drug used to prevent or treat nausea and vomiting, as well as an antipsychotic. It is administered through injection, usually in a hospital or clinic setting, and cannot be stored at home. In 2001, the FDA issued a black box warning for droperidol, citing concerns about QT prolongation and torsades de pointes, which led to a decline in its use. However, the warning has been criticized for lacking scientific evidence, and droperidol has since made a comeback, with some hospitals working to reinstate its use.

Explore related products

The Law of Healthcare Administration, Ninth Edition (9)

$89.13 $132

Lean Hospitals: Improving Quality, Patient Safety, and Employee Engagement, Third Edition

$36.9 $61.99

The Checklist Manifesto: How to Get Things Right

$9.99 $18.99

Hospitals: What They Are and How They Work: . (Griffin, Hospitals)

$115.94 $177.95

Management Lessons from Mayo Clinic: Inside One of the World's Most Admired Service Organizations

$19.2 $28

Care After Covid: What the Pandemic Revealed Is Broken in Healthcare and How to Reinvent It

$28.8 $32

Droperidol is an antiemetic drug used to prevent nausea and vomiting after surgery

The drug was discovered in 1961 and has been used effectively for decades, with millions of doses administered without incident. Droperidol is particularly useful for patients who are moderately agitated, disruptive, and require calming medication but do not pose a threat to themselves or others. It is also used to produce tranquilization and reduce nausea and vomiting during surgical and diagnostic procedures.

While Droperidol is considered safe, it is not without risks. Some patients have experienced dangerous QT prolongation and torsades after taking Droperidol, though these cases are rare and often involve high doses or interactions with other medications. It is important for patients to disclose their full medical history, including any medications they are taking, to their doctor before receiving Droperidol.

Side effects of Droperidol may include drowsiness, dizziness, allergic reactions, and in rare cases, neuroleptic malignant syndrome (NMS). Patients should be closely monitored by their doctor after receiving the medication to check for any unwanted effects. Droperidol may also interact with other medications, including CNS depressants, and patients should consult their doctor before taking any other medications after receiving Droperidol.

Explore related products

Challenging Operations: Medical Reform and Resistance in Surgery

$33.04 $35

PDC Healthcare AN-4 Anesthesia Removable Tape with Date, Time & Initial, Droperidol Mg/Ml, 333 Imprints, Salmon, 1/2" Width, 500" Length

$10.31

It is also used as an antipsychotic for patients with severe agitation

Droperidol is an antidopaminergic drug used to prevent or treat nausea and vomiting after surgery or other procedures. It is also used as an antipsychotic in cases of severe agitation in psychotic patients who refuse oral medication. It is administered in doses ranging from 5 to 10 mg, either intravenously or intramuscularly.

Droperidol is a butyrophenone, a typical antipsychotic agent with a similar profile to haloperidol, and acts as a potent dopamine D2 receptor antagonist with some histamine and serotonin antagonist activity. It is particularly useful in patients who are agitated but not dangerous, disruptive, and require calming medication but are not an immediate threat to themselves or others.

The use of droperidol as an antipsychotic has been somewhat controversial. In 2001, the Food and Drug Administration (FDA) in the United States issued a widely criticised warning, citing concerns about QT prolongation and torsades de pointes. This warning recommended an ECG prior to dosing and telemetry for two to three hours following administration. This caused droperidol to disappear from hospitals in the US, UK, and many other countries. However, the evidence for this warning is disputed, with only nine reported cases of torsades in 30 years, all of which received extremely high doses. Droperidol has a long record of safety, with millions of doses administered without incident, and its cardiovascular safety is supported by multiple studies.

Despite the controversy, droperidol has seen a re-emergence in recent years, with the manufacturer American Regent reintroducing it to the US market in 2019. This is due in part to the outcry from the medical community, who highlighted the apparent lack of sound scientific evidence in the FDA's decision. Droperidol is now once again available in hospitals and clinics, although its use is carefully monitored by healthcare professionals.

Droperidol is administered by a trained health professional in a hospital or clinic setting

Droperidol is a butyrophenone antidopaminergic drug, which acts as a potent D2 (dopamine receptor) antagonist. It is used to prevent nausea and vomiting after surgery or other procedures. It is also used as an antipsychotic and a rapid sedative in intensive care treatment. Droperidol is administered by a trained health professional in a hospital or clinic setting.

It is important to note that droperidol is given only by injection and must be administered by a trained health professional, such as a nurse, or under the direct supervision of a doctor. This is because droperidol has been associated with some serious side effects, including neuroleptic malignant syndrome (NMS), which can cause symptoms such as difficulty breathing, a fast heartbeat, high fever, and severe muscle stiffness.

In 2001, the FDA issued a warning regarding the use of droperidol, citing concerns of QT prolongation and torsades de pointes. This warning led to a significant decrease in the use of droperidol in hospitals and it even disappeared from some hospital formularies. However, the evidence for this warning has been disputed, with only a small number of reported cases of torsades, and many of these occurring at extremely high doses.

Despite the controversy, droperidol remains a valuable medication in certain situations, particularly for treating agitation in patients who are not an immediate threat to themselves or others. It is also often used in combination with other medications, such as haloperidol and lorazepam, to enhance its effectiveness.

When receiving droperidol, it is important to inform your healthcare professional of any other medications you are taking, as well as any allergies or medical history, especially heart rhythm problems.

The drug was temporarily removed from hospitals due to safety concerns and a lack of scientific evidence

Droperidol is an antidopaminergic drug used to prevent nausea and vomiting after surgery or other procedures. It is also used as an antipsychotic and a sedative in intensive care treatment. In 2001, the Food and Drug Administration (FDA) issued a black box warning, citing concerns of QT prolongation and torsades de pointes. This warning recommended a screening ECG prior to dosing and telemetry for two to three hours following administration.

The FDA's decision was met with substantial criticism from the medical community, which questioned the lack of sound scientific evidence behind it. It was noted that the data used by the FDA consisted of a small number of patients receiving varying doses of droperidol, with the majority of doses far exceeding the usual antiemetic dosing. Additionally, it was observed that many patients who experienced cardiac complications had confounding factors that were not accounted for by the FDA. As a result of this warning and the emergence of alternative medications, the use of droperidol declined, and it eventually disappeared from hospitals in the United States, the United Kingdom, and other places.

Despite the concerns, droperidol has a long record of safety, with millions of doses administered without incident. Studies have supported its cardiovascular safety, finding no cases of torsades de pointes among over 1,200 agitated patients who received the drug. While there have been rare reports of torsades and death associated with droperidol, these cases typically involve extremely high doses or the use of multiple medications. In 2019, the pharmaceutical manufacturer American Regent, Inc. reintroduced droperidol to the US market, and it is now once again available in hospitals and clinics.

Droperidol has since been reintroduced to the market, but its use is still disputed by some

Droperidol is an antidopaminergic drug used to prevent nausea and vomiting after surgery or other procedures. It is also used as an antipsychotic and as a rapid sedative in intensive care treatment. It was discovered in 1961 and has been used in doses ranging from 0.625 to 10 mg, given as an injection into a muscle or a vein.

In 2001, the Food and Drug Administration (FDA) issued a warning about the use of droperidol, citing concerns of QT prolongation and torsades de pointes. This warning led to a significant decrease in the use of droperidol, with hospitals erecting barriers and requirements that blocked its use. In 2012, the two manufacturers in the US stopped producing it, and it disappeared from hospitals in the United States, the United Kingdom, and many other places.

However, the evidence for the FDA's warning is disputed. There have been case reports of torsades and death with droperidol, but these usually involve extremely high doses or a cocktail of other medications. Droperidol has a long record of safety, with millions of doses administered without incident, and some argue that it is safer than other drugs like midazolam or morphine. Additionally, the data used by the FDA has been criticized for consisting of a small number of patients receiving varying doses, many of whom had confounding factors that were not accounted for.

Despite the controversy, droperidol has been reintroduced to the US market by the manufacturer American Regent as of February 2019. It is now available for use in hospitals and clinics, but its use is still disputed by some due to concerns about its potential side effects and the erosion of knowledge regarding its clinical use. Some hospitals are working to get droperidol back on their formularies, but it is not yet clear if it will fully reemerge as a safe and effective antiemetic.

Frequently asked questions